| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 2.06 [0.93, 4.56] | | < 1 | | 0% | 1 study (1/-) | 3.7 % | NA | not evaluable | | crucial | - |
| progression or deaths (PFS) | 1.22 [0.67, 2.22] | | < 1 | | 0% | 1 study (1/-) | 25.8 % | NA | not evaluable | | important | - |
| DCR | 0.80 [0.43, 1.46] | | > 1 | | 0% | 1 study (1/-) | 22.9 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 1.07 [0.67, 1.71] | | > 1 | | 0% | 1 study (1/-) | 61.1 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| AE (any grade) | 1.40 [0.57, 3.44] | | < 1 | | 0% | 1 study (1/-) | 22.9 % | NA | not evaluable | | non important | - |
| AE (grade 3-4) | 2.17 [1.36, 3.46] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 1.64 [0.66, 4.08] | | < 1 | | 0% | 1 study (1/-) | 14.5 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (any grade) | 2.62 [1.45, 4.72] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
| SAE (any grade) | 1.84 [1.16, 2.92] | | < 1 | | 0% | 1 study (1/-) | 0.5 % | NA | not evaluable | | non important | - |
| TRAE leading to death (grade 5) | 3.00 [0.60, 15.11] | | < 1 | | 0% | 1 study (1/-) | 9.2 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (any grade) | 2.91 [1.43, 5.93] | | < 1 | | 0% | 1 study (1/-) | 0.2 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 1.95 [0.07, 58.66] | | < 1 | | 0% | 1 study (1/-) | 35.2 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 1.95 [0.07, 58.66] | | < 1 | | 0% | 1 study (1/-) | 35.2 % | NA | not evaluable | | non important | - |
| Diabetes TRAE (grade 3-4) | 1.95 [0.07, 58.66] | | < 1 | | 0% | 1 study (1/-) | 35.2 % | NA | not evaluable | | non important | - |
| Dry skin TRAE (grade 3-4) | 1.95 [0.07, 58.66] | | < 1 | | 0% | 1 study (1/-) | 35.2 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 1.95 [0.07, 58.66] | | < 1 | | 0% | 1 study (1/-) | 35.2 % | NA | not evaluable | | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 0.97 [0.02, 49.37] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 5.94 [0.29, 119.61] | | < 1 | | 0% | 1 study (1/-) | 12.5 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.97 [0.02, 49.37] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 3.93 [0.18, 87.94] | | < 1 | | 0% | 1 study (1/-) | 19.7 % | NA | not evaluable | | non important | - |
| Myocarditis TRAE (grade 3-4) | 1.95 [0.07, 58.66] | | < 1 | | 0% | 1 study (1/-) | 35.2 % | NA | not evaluable | | non important | - |
| Pancreatitis TRAE (grade 3-4) | 1.95 [0.07, 58.66] | | < 1 | | 0% | 1 study (1/-) | 35.2 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 0.97 [0.02, 49.37] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
| Pruritic rash TRAE (grade 3-4) | 1.95 [0.07, 58.66] | | < 1 | | 0% | 1 study (1/-) | 35.2 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 27.63 [1.62, 470.16] | | < 1 | | 0% | 1 study (1/-) | 1.2 % | NA | not evaluable | | non important | - |
| Stevens-Johnson syndrome TRAE (grade 3-4) | 1.95 [0.07, 58.66] | | < 1 | | 0% | 1 study (1/-) | 35.2 % | NA | not evaluable | | non important | - |
| Thyroiditis TRAE (grade 3-4) | 0.97 [0.02, 49.37] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| Anaemia AE (grade 3-4) | 1.92 [0.79, 4.67] | | < 1 | | 0% | 1 study (1/-) | 7.6 % | NA | not evaluable | | non important | - |
| Back pain AE (grade 3-4) | 1.64 [0.39, 7.01] | | < 1 | | 0% | 1 study (1/-) | 25.2 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 3.93 [0.18, 87.94] | | < 1 | | 0% | 1 study (1/-) | 19.7 % | NA | not evaluable | | non important | - |
| Cough AE (grade 3-4) | 0.97 [0.02, 49.37] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 0.64 [0.11, 3.91] | | < 1 | | 0% | 1 study (1/-) | 68.3 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 10.03 [0.54, 185.37] | | < 1 | | 0% | 1 study (1/-) | 6.3 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 12.13 [0.67, 219.12] | | < 1 | | 0% | 1 study (1/-) | 4.7 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 1.64 [0.39, 7.01] | | < 1 | | 0% | 1 study (1/-) | 25.2 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 2.96 [0.30, 28.78] | | < 1 | | 0% | 1 study (1/-) | 17.7 % | NA | not evaluable | | non important | - |
| Neutropenia AE (grade 3-4) | 1.04 [0.50, 2.20] | | < 1 | | 0% | 1 study (1/-) | 45.6 % | NA | not evaluable | | non important | - |
| Peripheral oedema AE (grade 3-4) | 1.95 [0.07, 58.66] | | < 1 | | 0% | 1 study (1/-) | 35.2 % | NA | not evaluable | | non important | - |
| Pneumonia AE (grade 3-4) | 1.31 [0.44, 3.89] | | < 1 | | 0% | 1 study (1/-) | 31.1 % | NA | not evaluable | | non important | - |
| Pyrexia AE (grade 3-4) | 7.97 [0.42, 152.17] | | < 1 | | 0% | 1 study (1/-) | 8.6 % | NA | not evaluable | | non important | - |
| Rash AE (grade 3-4) | 6.04 [0.72, 50.82] | | < 1 | | 0% | 1 study (1/-) | 5.0 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 3.93 [0.18, 87.94] | | < 1 | | 0% | 1 study (1/-) | 19.7 % | NA | not evaluable | | non important | - |
